<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387086</url>
  </required_header>
  <id_info>
    <org_study_id>GELI</org_study_id>
    <nct_id>NCT02387086</nct_id>
  </id_info>
  <brief_title>Gefitinib Combined With Thalidomide to Treat NSCLC</brief_title>
  <official_title>A Phase III, Multi Center, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination Gefitinib With Thalidomide in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer With EGFR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bai Jun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaanxi Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether thalidomide can improve the effectiveness&#xD;
      of the gefitinib in NSCLC patients with EGFR mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine the 1 year progression-free survival(PFS) rate of the combination of thalidomide&#xD;
      with gefitinib in patients who harbors EGFR mutations.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To evaluate the objective response rate and 2 years overall survival of this combination&#xD;
           therapy;&#xD;
&#xD;
        2. To evaluate the safety and tolerability of this combination therapy;&#xD;
&#xD;
        3. To acquire preliminary data regarding the effects of thalidomide on interleukin-2 level&#xD;
           in serum.&#xD;
&#xD;
      Treatment will be administered on an outpatient basis. Thalidomide starting at a dose of 50mg&#xD;
      QD at night. After one week, increase the dose to 100mg QD at night.&#xD;
&#xD;
      Aspirin will be administered at 100mg QD continuously. Gefitinib will be administered at&#xD;
      250mg QD continuously. Maintenance Therapy patients responding to this therapy will be&#xD;
      maintained with gefitinib、thalidomide and aspirin.&#xD;
&#xD;
      Duration of Therapy&#xD;
&#xD;
      In the absence of treatment delays due to adverse events, treatment may continue until one of&#xD;
      the following criteria applies:&#xD;
&#xD;
        1. Disease progression,&#xD;
&#xD;
        2. Intercurrent illness that prevents further administration of treatment,&#xD;
&#xD;
        3. Unacceptable adverse events(s),&#xD;
&#xD;
        4. Patient decides to withdraw from the study, or&#xD;
&#xD;
        5. General or specific changes in the patient's condition render the patient unacceptable&#xD;
           for further treatment in the judgment of the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>one year progression-free survival of the patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>the Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>2 years Overall Survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>IL-2 level</measure>
    <time_frame>2 years</time_frame>
    <description>IL-2 level in serum of patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>A:gefitinib and thalidomide/aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B:Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <arm_group_label>A:gefitinib and thalidomide/aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>B:Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <arm_group_label>A:gefitinib and thalidomide/aspirin</arm_group_label>
    <arm_group_label>B:Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>A:gefitinib and thalidomide/aspirin</arm_group_label>
    <arm_group_label>B:Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be NSCLC confirmed by Histological or cytological;&#xD;
&#xD;
          -  The NSCLC harbors EGFR-mutation and are previously untreated&#xD;
&#xD;
          -  Patient must have measurable lesion and in stage IIIB or IV disease (includes M1a, M1b&#xD;
             stages or recurrent disease) (according to the 7th edition of the tumor node&#xD;
             metastasis (TNM) classification system).&#xD;
&#xD;
          -  Patients be age &gt;18 years and &lt; 75 years.&#xD;
&#xD;
          -  Patients must have a Life Expectancy of greater than 12 weeks.&#xD;
&#xD;
          -  Patients must have an ECOG performance status 0 to 2.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below, within one week&#xD;
             prior to randomization: absolute neutrophil count&gt;1,500/mL platelets&gt;100,000/mL total&#xD;
             bilirubin: within normal institutional limits AST/ALT&lt;2.5X institutional upper limit&#xD;
             of normal creatinine≤1.5X institutional upper limit of normal urine dipstick for&#xD;
             proteinuria of &lt; less than 1+. If urine dipstick is &gt; 1+ then a 24 hour urine for&#xD;
             protein must demonstrate &lt;500mg of protein in 24 hours to allow participation in the&#xD;
             study.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
          -  Patients must have an international normalized ratio (INR) &lt; 1.5 and a partial&#xD;
             thromboplastin time (PTT) no greater than upper limits of normal within 1 week prior&#xD;
             to randomization.&#xD;
&#xD;
          -  Patients with a history of hypertension must be well-controlled (&lt;150 systolic/&lt;100&#xD;
             diastolic) on a stable regimen of anti-hypertensive therapy.&#xD;
&#xD;
          -  Patients must be able to swallow tablets.&#xD;
&#xD;
          -  Patients must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uncontrolled illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situation that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Patients receiving therapeutic anticoagulation. Prophylactic anticoagulation of venous&#xD;
             access devices is allowed provided Section 3.10 is met. Caution should be taken on&#xD;
             treating patients with low dose heparin or low molecular weight heparin for DVT&#xD;
             prophylaxis during treatment with bevacizumab as there may be an increased risk of&#xD;
             bleeding.&#xD;
&#xD;
          -  Patients cannot administer aspirin for the risk of bleeding or having stomach ulcers.&#xD;
&#xD;
          -  Prior use of chemotherapy.&#xD;
&#xD;
          -  Patients receiving immunotherapy, hormonal-therapy and or radiotherapy within 2 weeks&#xD;
             prior to entering the study. Note: Those who have not recovered from adverse events&#xD;
             due to these agents administered will be considered ineligible.&#xD;
&#xD;
          -  Patients receiving any other investigational agents.&#xD;
&#xD;
          -  Patients with uncontrolled brain metastasis. Note: Patients with brain metastases must&#xD;
             have stable neurologic status following local therapy (surgery or radiation) for at&#xD;
             least 2 weeks, and must be without neurologic dysfunction that would confound the&#xD;
             evaluation of neurologic and other adverse events.&#xD;
&#xD;
          -  Patients with a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to thalidomide、gefitinib and aspirin or other agents&#xD;
             used in the study are excluded.&#xD;
&#xD;
          -  Women that are pregnant or breastfeeding Note: Pregnant women are excluded from this&#xD;
             study because the agents used in this study may be teratogenic to a fetus. Because&#xD;
             there is an unknown but potential risk for adverse events in nursing infants secondary&#xD;
             to treatment of the mother with thalidomide, breastfeeding women are also excluded&#xD;
             from this study.&#xD;
&#xD;
          -  HIV-positive Patients that are on combination antiretroviral therapy due to the&#xD;
             potential for lethal infections when treated with marrow-suppressive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Bai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaanxi Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Bai</last_name>
    <phone>+86-13186055863</phone>
    <email>baijun@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Lei</last_name>
    <phone>+86-18682984013</phone>
    <email>leiyu1981@126.com</email>
  </overall_contact_backup>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shaanxi Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Bai Jun</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>gefitinib</keyword>
  <keyword>thalidomide</keyword>
  <keyword>NSCLC</keyword>
  <keyword>EGFR mutation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

